

RESEARCH ARTICLE

Time at Treatment of Severe Retinopathy of Prematurity in China: Recommendations for Guidelines in More Mature Infants

Yi Chen^{1‡}, Jing Feng^{1‡}, Clare Gilbert², Hong Yin¹, Jianhong Liang¹, Xiaoxin Li^{1*}

1 Department of Ophthalmology, People's Hospital, Peking University, & Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing, China, **2** International Centre for Eye Health, Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, United Kingdom

‡ These authors are co-first authors on this work.

* drli_xiao_xin@163.com

Abstract

Purpose

To investigate the postmenstrual (PMA) age at treatment of severe retinopathy of prematurity (i.e. Type 1 prethreshold or threshold) in infants in a tertiary referral center in China.

Principal Findings

76.6% (359/469) of infants were treated for threshold disease. 67.5% (317/469) of infants had a birth weight (BW) of 1250g or above and almost 30% (126) had a gestational age (GA) of 32 weeks or above. There was little difference in the characteristics of infants treated for Type 1 prethreshold or threshold ROP. After controlling for GA, PMA age at treatment was highest in infants with BW \geq 2000g (mean PMA 40.3 \pm 4.4 weeks, $p < 0.001$); after controlling for BW, higher GA was associated with higher PMA at treatment (mean PMA 41.5 weeks for gestational age $>$ 34 weeks, $p < 0.001$). For every three weeks increase in GA there was a two-week increase in PMA at treatment ($R^2 = 0.20$, $p < 0.001$). The time at treatment of Type 1 prethreshold disease was similar to that for threshold disease i.e. chronological age 5.6–7.4 weeks, or PMA 34.1–40.2 weeks but the lower end of the 95% confidence interval for chronological age for Type 1 prethreshold disease among infants with BW \geq 2000g was 3.7 weeks (i.e. before the recommended interval of 4–6 weeks after birth).

Significance

The Chinese guidelines regarding timing of the first examination are appropriate for infants with BW $<$ 2000g, but more mature infants should be examined a little earlier, at 3 weeks after birth, in order to detect Type 1 prethreshold disease which has a better prognosis than threshold.



OPEN ACCESS

Citation: Chen Y, Feng J, Gilbert C, Yin H, Liang J, Li X (2015) Time at Treatment of Severe Retinopathy of Prematurity in China: Recommendations for Guidelines in More Mature Infants. PLoS ONE 10(2): e0116669. doi:10.1371/journal.pone.0116669

Academic Editor: Tailoi Chan-Ling, University of Sydney, AUSTRALIA

Received: June 30, 2014

Accepted: February 9, 2014

Copyright: © 2015 Chen et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper.

Funding: The authors have no support or funding to report.

Competing Interests: The authors have declared that no competing interests exist.

Introduction

Retinopathy of prematurity (ROP) is emerging as a major cause of blindness in children in the middle-income countries of Latin American and Asia (China, Thailand, India, and Vietnam) where neonatal intensive care services have improved the survival of high-risk neonates.[1–5] ROP is can be very variable in its severity and outcome. If disease with a high probability of progression to retinal detachment is detected early and treated with peripheral retinal laser, the risk of blindness is reduced.[6,7] However, if the disease progresses to stage 5 ROP the visual acuity prognosis after vitro-retinal surgery is usually poor.[8–10] Thus, timing is an important factor in the detection of ROP requiring laser treatment, as the disease can advance very quickly and delayed treatment reduces the likelihood of a good outcome.

Our previous study in China found that infants who developed severe ROP were more mature and bigger than infants similarly affected in high income countries, and this is reflected in the wider screening criteria being used in China (i.e. birth weight (BW) ≤ 2000 g or gestational age (GA) ≤ 34 weeks GA) [11–14]. The rate of progression of ROP, and the period after birth during which disease requiring treatment is likely to develop are important as they influence timing of the first and subsequent examinations. [15,16] Data from the control arm of the CRYO-ROP trial indicated that more premature infants developed threshold disease at an earlier postmenstrual age (PMA) than more mature infants, and this is reflected in some country's national ROP guidelines.[17,18] For example, the US guidelines recommend that infants with a GA of 22 weeks or less be examined at up to 9 weeks after birth which translate to a PMA age of 31 weeks.[13] Infants born at 30 weeks should be examined 4 weeks after birth, which translates to a PMA age of 34 weeks. The UK guidelines are similar [14] However, all the natural history data from the CRYO-ROP trial were on infants with BWs < 1251 g, being much lower than infants who are currently developing ROP requiring treatment in China.[19]

Indeed, the Chinese guidelines recommend that the initial examination be undertaken 4–6 weeks after birth, or at 32–34 weeks PMA.[12,13] However, these guidelines may not be applicable for the more mature infants who develop severe ROP in China where there is greater exposure to known risk factors that might influence and accelerate the progression of ROP. If more mature infants develop ROP requiring treatment more quickly than those with GA < 32 weeks, then some infants may be examined too late in China. There is little information regarding the PMA at which more mature infants are at risk of ROP in middle and low-income countries although a study in Vietnam showed that PMA at threshold in Vietnam was similar to that in developed countries. [20] The aim of this study was to investigate the PMA at treatment of severe ROP among more mature infants compared with less mature infants, to assess whether the Chinese guidelines regarding timing of the first examination need to be modified.

The study was undertaken in the Department of Ophthalmology, People's Hospital of Peking University, which is the main ROP referral center in northern China. Most units in northern China only screen infants and refer those needing treatment to this hospital as lasers or skills in treatment are not yet available in many units.

Patients and Methods

The study was conducted in accordance with the Declaration of Helsinki, and we received approval from the Investigational Review Board of the People's Hospital affiliated with Peking University. Informed consent for all examinations and procedures was obtained from the parents or guardians, who provided their written informed consent to participate.

Our indications for laser treatment in study were eyes Type 1 prethreshold ROP or threshold ROP depending on the stage of disease at presentation.[21] Data were retrieved on all infants treated with laser for Type 1 prethreshold or threshold ROP in the hospital from 2004 to

2011. Medical histories were reviewed and the following data extracted: single or multiple birth, BW, GA, sex, and PMA at treatment (GA + chronological age in weeks). The stage of ROP at the first procedure was recorded. If the baby had different stages of ROP in each eye, the more advanced stage was recorded as the stage for the baby. ROP was classified according to the international classification.[22]

Mean BW and GA were determined for infants treated for Type 1 prethreshold and for threshold ROP. Associations between BW and GA with timing of ROP treatment were determined based on analysis of variance (ANOVA) by considering the effects of BW and GA simultaneously. A commercially available statistical software package (SPSS for Windows version 17.0; SPSS Inc., Chicago, IL) was used for analysis. A one-sample Kolmogorov–Smirnov test was performed to determine whether the samples were normally distributed. Differences between two groups were estimated with a nonparametric Mann–Whitney rank sum test and t test when appropriate. Parameters were compared using the Kruskal–Wallis H test and one-way ANOVA to compare variables among different groups. Two-tailed probabilities less than 0.05 were considered statistically significance.

Results

A total of 469 infants were treated between 2004 and 2011. 165 were female (35.2%), 68 were twins (14.3%), and one was a triplet (0.01%). The vast majority were treated at the time of diagnosis or within a few days. 76.6% (359) were treated at the threshold level of disease (Table 1). 67.5% (317) of infants had a BW of 1250g or above and almost 30% (126) had a GA of 32 weeks or above.

There was little difference in the characteristics of infants treated for Type 1 prethreshold disease or for threshold ROP (Table 1). Four infants (0.8%) had BWs and GAs outside the Chinese screening criteria (≤ 2000 g BW or ≤ 34 weeks GA) (Fig. 1).

Both BW and GA were independently associated with PMA and chronological age at treatment. After controlling for the effect of GA, PMA at treatment was highest in infants with $BW \geq 2000$ g (mean PMA 40.3 ± 4.4 weeks, $p < 0.001$) (Table 2, Fig. 2A). After controlling for the effect of BW, higher GA was associated with higher PMA at treatment (mean PMA 41.5 weeks for GA > 34 weeks) ($p < 0.001$) (Table 2, Fig. 2B). Linear regression indicated that for every three weeks increase in GA there was only a two-week increase in PMA at treatment ($R^2 = 0.20$, $p < 0.001$) (Fig. 3B).

The timing of treatment for Type 1 prethreshold and threshold disease was similar to that for the whole group of infants i.e. 5.6–7.4 weeks chronological age, or 34.1–40.2 weeks PMA (Table 3, Table 4). However, the lower end of the 95% confidence interval for chronological age at treatment of infants with BWs ≥ 2000 g treated for Type 1 prethreshold disease was 3.7 weeks (i.e. before the recommended interval of 4–6 weeks after birth) (Table 3). These infants with BW ≥ 2000 g had a mean gestational age of 33.0 weeks (range: 30.1–35.9 weeks).

Discussion

With the increased survival of premature infants in China, the incidence of severe ROP is predicted to increase.[12,23] In our previous study, we reported a repeat of the first epidemic of severe ROP from 2001 to 2004 in China, and showed that larger and more mature infants are also at risk.[24] In a more recent study the findings were similar with mean BW and mean GA at treatment being 1418 g and 30 weeks respectively. There may be many reasons for this first epidemic picture in China, but lack of meticulous monitoring of blood oxygen levels, and high mortality rates in very low BW babies are likely explanations.

Table 1. Birth weight and gestational age of infants treated for prethreshold and threshold ROP.

	Prethreshold (N = 110, 23.5%)		Threshold (N = 359, 76.5%)		Total (N = 469, 100%)		P value
	Mean ± 1SD	Median (95% CI)	Mean ± 1SD	Median (95% CI)	Mean ± 1SD	Median (95% CI)	
BW (g)	1415.3±347.3	1350.0 (1349.9–1480.6)	1419.4±350.2	1350.0 (1383.0–1455.6)	1418.4±349.2	1350.0 (1386.8–1450.0)	0.86 ^a
GA (weeks)	30.3±2.2	30.0 (29.9–30.7)	30.3±2.1	30.0 (30.0–30.5)	30.3±2.1	30.0 (30.1–30.5)	0.69 ^a
PMA (weeks)	38.1±3.6	37.0 (37.5–38.8)	38.0±3.8	38.0 (37.6–38.4)	38.0±3.8	37.0 (37.7–38.4)	0.83 ^a
CA (weeks)	7.8±3.4	8.0 (7.2–8.5)	7.7±3.5	8.0 (7.4–8.1)	7.7±3.5	8.0 (7.4–8.1)	0.71 ^a

BW = birth weight; GA = gestational age; PMA = postmenstrual age; CA = chronological age

^a Comparing between prethreshold vs. threshold.

doi:10.1371/journal.pone.0116669.t001

The criteria for ROP screening in countries with advanced neonatal services are similar, using GA and BW cutoffs based on epidemiologic data. The goal is to ensure that all infants at risk of severe ROP are examined. In this study the vast majority of infants fell within the current Chinese screening guidelines (99.2%), but the wider screening range greatly increases the number of infants to be examined.

Data from CRYO-ROP and ET-ROP studies showed that infants with BWs <1,251g developed threshold ROP at a median PMA of 37 weeks, and Type 1 prethreshold at a slightly earlier PMA (median 36 weeks). [15,25] Our results are similar as infants with BW <1250g developed severe ROP at a median PMA at treatment of 37 weeks. These findings suggest that the progress of the disease is similar across ethnic and racial groups despite exposure to different risk factors. However, none of the earlier studies included more mature infants. Our study of GA categories showed a similar trend, for example those whose GA <28 weeks were treated at a PMA of 35 weeks, and those with GA 32–33 weeks were treated at a PMA of 38 weeks. These findings show that in more mature infants the interval between birth and the onset of severe ROP continues to shorten.

Many factors are involved in the pathogenesis of ROP which are also likely to influence the time of onset and rate of progression. [26] In our study, linear regression indicated that for every three weeks increase in GA there was a two-week increase in PMA at treatment, suggesting that GA is a better predictor of time to development of severe disease than BW, as had been




Figure 1. Birth weight against gestational age of 469 infants treated for threshold or prethreshold ROP. Dotted line indicates Chinese screening criteria.

doi:10.1371/journal.pone.0116669.g001

Table 2. Postmenstrual and chronological age at treatment, by birth weight and gestational age (all infants).

Birth weight categories	N	%	Postmenstrual age (weeks)		Chronological age (weeks)	
			Mean ± 1SD	Median (95% CI)	Mean ± 1SD	Median (95% CI)
<1250 g	152	32.4%	37.4±3.7	37.0 (36.8–38.0)	8.3±3.5	8.0 (7.8–8.7)
1250–1499 g	137	29.2%	37.5±2.7	38.0 (37.1–38.0)	7.6±2.7	8.0 (7.1–8.0)
1500–1999 g	142	30.3%	38.3±3.8	37.0 (37.7–39.0)	7.2±3.5	7.2 (6.6–7.8)
≥2000 g	38	8.1%	40.3±4.4	40.0 (38.9–41.8)	7.6±4.3	6.9 (6.2–9.1)
Total	469		38.0±3.6	37.0 (37.6–38.3)	7.7±3.4	8.0 (7.4–8.0)
P-value			0.001*		0.001*	
Gestational age categories						
<28 weeks	28	6.0%	35.4±3.3	35 (34.1–36.7)	8.7±3.3	8.0 (7.4–10.0)
28–31 weeks	315	67.2%	37.4±3.5	37 (37.1–37.8)	8.0±3.4	8.0 (7.6–8.3)
32–33 weeks	94	20.0%	39.5±3.7	38 (38.7–40.2)	7.1±3.8	6.0 (6.4–7.9)
≥34 weeks	32	6.8%	41.5±3.7	40 (40.2–42.8)	6.8±3.5	6.0 (5.6–8.0)
Total	469		38.0±3.6	37.0 (37.6–38.3)	7.7±3.4	8.0 (7.4–8.0)
P-value			<0.001*		<0.001*	

* Statistically significant differences at $p < 0.05$

doi:10.1371/journal.pone.0116669.t002

found in other studies. Our study further confirms what is already known about the influence of GA on the timing of the first examination and the time period after birth at which disease requiring treatment is likely to develop, which is a critical factor for ROP programs. [14] However, there is potential for error in the calculation of GA which can be calculated from the start of the last menstrual period, and by ultrasound scanning which is more accurate. [27] However, up to 30% of women have long or irregular cycles [28] and some mothers do not remember the exact date of their last menstrual period.

Based on published data from the CRYO-ROP study, the number of early screening examinations cannot safely be reduced using a single criterion. Using chronological age alone will increase the risk of missing the onset of threshold ROP in larger BW infants while PMA alone will increase the risk in lower BW infants. The data from Hutchinson et al. also suggest that the first examination can often be safely delayed using the combined criteria of chronological and PMA. [29] The current Chinese guidelines recommend that the first examination be at 4–6 weeks after birth, or 32–34 weeks PMA, which is similar to the US and UK guidelines. [11–14] Data from our study showed that the timing of infants with ROP requiring treatment was 5.6–7.4 weeks chronological age and 34.1–40.2 weeks PMA. The ETROP study indicated that early treatment of “high-risk prethreshold ROP” significantly reduced unfavourable




Figure 2. Box plot of postmenstrual age at the time of diagnosis of ROP needing treatment, by birth weight ($p = 0.001$) (A); Box plot of postmenstrual age at the time of diagnosis of ROP needing treatment, by gestational age ($p < 0.001$) (B).

doi:10.1371/journal.pone.0116669.g002




Figure 3. Plot of birth weight against postmenstrual age at treatment (A); Plot of gestational age against postmenstrual age at treatment (B).

doi:10.1371/journal.pone.0116669.g003

outcomes to a clinically important degree.[21] As treatment at Type 1 prethreshold disease has a better prognosis than treatment at threshold, it is desirable that timing of the first examination be set to detect Type 1 prethreshold ROP.[25] In our study the median chronological age at treatment of Type 1 prethreshold disease amongst infants with BW \geq 2000g was before the timing of the first examination recommended in the guidelines. In China infants with BW \geq 2000g should, therefore, be examined at three weeks after birth, which may have the added advantage that the first examination will be undertaken on a higher proportion of infants before discharge.

In our study there were more male than female infants, which probably reflects the preponderance of male children in the population [30] [An additional factor may relate to differences in health seeking behavior between parents of boys compared with girls.

The limitation of our study was the study design, as we performed a retrospective, observation study of data extracted from medical records and databases. Thus, our findings should be interpreted with caution. Ideally, a large, carefully designed, prospective population-based cohort study of ROP should be conducted throughout China.

In conclusion, the recommended timing of the first examination is appropriate for less mature infants with BW <2000g, but bigger infants with BW \geq 2000g should be examined a little earlier at 3 weeks after birth, to detect Type 1 prethreshold disease when the prognosis is better than at threshold.

Table 3. Postmenstrual and chronological age at treatment, by birth weight and gestational age (prethreshold).

Birth weight categories	N	%	Postmenstrual age (weeks)		Chronological age (weeks)	
			Mean \pm 1SD	Median (95%CI)	Mean \pm 1SD,	Median (95%CI)
<1250 g	36	32.7%	37.5 \pm 3.9	36.5 (36.2–38.8)	8.5 (3.7)	8.0 (7.3–9.8)
1250–1499 g	29	26.4%	38.6 \pm 3.0	38.0 (37.5–39.7)	8.7 (2.9)	8.0 (7.6–9.8)
1500–1999 g	35	31.8%	37.8 \pm 3.4	37.0 (36.6–39.0)	6.7 (3.2)	6.0 (5.6–7.8)
\geq 2000 g	10	9.1%	39.1 \pm 3.3	38.5 (36.7–41.5)	6.1 (3.4)	6.5 (3.7–8.5)
Total	110		38.0 \pm 3.4	37.0 (37.4–38.7)	7.8 (3.4)	8.0 (7.1–8.4)
P-value			0.158		0.01*	
Gestational age categories						
<28 weeks	6	5.4%	34.8 \pm 1.9	34.5 (32.8–36.9)	8.5 \pm 2.2	8.0 (6.2–10.8)
28–31 weeks	73	66.4%	37.8 \pm 3.5	37.0 (36.9–38.6)	8.3 \pm 3.6	8.0 (7.5–9.1)
32–33 weeks	23	20.9%	38.6 \pm 2.9	38.0 (37.3–39.9)	6.3 \pm 3.0	6.0 (5.0–7.7)
\geq 34 weeks	8	7.3%	41.1 \pm 2.9	41.0 (38.7–43.5)	6.5 \pm 2.5,	7.0 (4.4–8.6)
Total	110		38.0 (3.4)	37.0 (37.4–38.7)	7.8 \pm 3.4	8.0 (7.1–8.4)
P-value			0.001*		0.092	

* Statistically significant differences at p<0.05

doi:10.1371/journal.pone.0116669.t003

Table 4. Postmenstrual and chronological age at treatment, by birth weight and gestational age (Threshold).

Birth weight categories	N	%	Postmenstrual age (weeks)		Chronological age (weeks)	
			Mean±1SD	Median (95%CI)	Mean±1SD	Median (95%CI)
<1250 g	116	32.3%	37.4±3.6	37.0 (36.7–38.0)	8.2±3.4	8.0 (7.6–8.9)
1250–1499 g	108	30.1%	37.2±2.5	37.6 (36.7–37.7)	7.3±2.5	8.0 (6.8–7.7)
1500–1999 g	107	29.8%	38.5±4.0	38.0 (37.7–39.2)	7.3±3.6	6.0 (6.6–8.0)
≥2000 g	28	7.8%	40.8±4.8	40.0 (38.9–42.6)	8.2±4.5	7.4 (6.5–9.9)
Total	359		37.9±3.7	38.0 (37.5–38.3)	7.7±3.4	8.0 (7.3–8.0)
P-value			0.001*		0.019	
Gestational age categories						
<28 weeks	22	6.1%	35.6±3.6	35.0 (34.0–37.2)	8.8±3.6	8.0 (7.2–10.4)
28–31 weeks	241	67.1%	37.3±3.1	37.0 (36.9–37.7)	7.8±3.1	8.0 (7.4–8.2)
32–33 weeks	71	19.8%	39.7±3.9	38.0 (38.8–40.7)	7.4±4.0	6.0(6.4–8.3)
≥34 weeks	25	7.0%	41.4±3.7	40.0 (39.8–42.9)	6.7±3.7	6.0 (5.1–8.2)
Total	359		38.0±3.7	38.0 (37.5–38.3)	7.7±3.4	8.0 (7.3–8.0)
P-value			<0.001*		0.001*	

* Statistically significant differences at $p < 0.05$

doi:10.1371/journal.pone.0116669.t004

Author Contributions

Conceived and designed the experiments: YC CG XL. Performed the experiments: YC JF CG HY JL XL. Analyzed the data: YC JF CG. Contributed reagents/materials/analysis tools: YC JF. Wrote the paper: YC JF CG.

References

- Gilbert C, Fielder A, Gordillo L, Quinn G, Semiglia R, et al. (2005) Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. *Pediatrics* 115: e518–525. PMID: [15805336](#)
- Gilbert C, Rahi J, Eckstein M, O'Sullivan J, Foster A (1997) Retinopathy of prematurity in middle-income countries. *Lancet* 350: 12–14. PMID: [9217713](#)
- Yang CY, Lien R, Yang PH, Chu SM, Hsu JF, et al. (2011) Analysis of incidence and risk factors of retinopathy of prematurity among very-low-birth-weight infants in North Taiwan. *Pediatr Neonatol* 52: 321–326. doi: [10.1016/j.pedneo.2011.08.004](#) PMID: [22192259](#)
- Limburg H, Gilbert C, Hon do N, Dung NC, Hoang TH (2012) Prevalence and causes of blindness in children in Vietnam. *Ophthalmology* 119: 355–361. doi: [10.1016/j.ophtha.2011.07.037](#) PMID: [22035577](#)
- Blencowe H, Lawn JE, Vazquez T, Fielder A, Gilbert C (2013) Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. *Pediatr Res* 74 Suppl 1: 35–49.
- Houston SK, Wykoff CC, Berrocal AM, Hess DJ, Murray TG (2013) Laser treatment for retinopathy of prematurity. *Lasers Med Sci* 28: 683–692. doi: [10.1007/s10103-011-1021-z](#) PMID: [22134790](#)
- Nicoara SD, Cristian C, Irimescu I, Stefanut AC, Zaharie G (2014) Diode laser photocoagulation for retinopathy of prematurity: outcomes after 7 years of treatment. *J Pediatr Ophthalmol Strabismus* 51: 39–45. doi: [10.3928/01913913-20131112-02](#) PMID: [24256550](#)
- Sinha R, Talawar P, Ramachandran R, Azad R, Mohan VK (2014) Perioperative management and post-operative course in preterm infants undergoing vitreo-retinal surgery for retinopathy of prematurity: A retrospective study. *J Anaesthesiol Clin Pharmacol* 30: 258–262. doi: [10.4103/0970-9185.130050](#) PMID: [24803769](#)
- Asano MK, Papakostas TD, Palma CV, Skondra D (2014) Visual outcomes of surgery for stage 4 and 5 retinopathy of prematurity. *Int Ophthalmol Clin* 54: 225–237. doi: [10.1097/IIO.000000000000012](#) PMID: [24613895](#)

10. Repka MX, Tung B, Good WV, Capone A, Shapiro MJ (2011) Outcome of eyes developing retinal detachment during the Early Treatment for Retinopathy of Prematurity study. *Arch Ophthalmol* 129: 1175–1179. doi: [10.1001/archophthalmol.2011.229](https://doi.org/10.1001/archophthalmol.2011.229) PMID: [21911664](https://pubmed.ncbi.nlm.nih.gov/21911664/)
11. The Chinese Medical Association (2005) Guidelines for therapeutic use of oxygen and prevention and treatment of retinopathy in premature infants. *Chinese Journal of Pediatrics* 41: 375–376.
12. Li X (2004) Characteristics and screening guideline of retinopathy of prematurity patients in China. *Chin J Ocul Fundus Dis* 20: 384–386.
13. Fierson WM (2013) American Academy of Pediatrics Section on Ophthalmology, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology Strabismus, American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. *Pediatrics* 131: 189–195. doi: [10.1542/peds.2012-2996](https://doi.org/10.1542/peds.2012-2996) PMID: [23277315](https://pubmed.ncbi.nlm.nih.gov/23277315/)
14. Wilkinson A, Haines L, Head K, Fielder A (2009) UK retinopathy of prematurity guideline. *Eye (Lond)* 23: 2137–2139. doi: [10.1038/eye.2008.128](https://doi.org/10.1038/eye.2008.128) PMID: [18836408](https://pubmed.ncbi.nlm.nih.gov/18836408/)
15. Palmer EA (2006) Costenbader Lecture. The factor of time in retinopathy of prematurity. *J AAPOS* 10: 500–506. PMID: [17189142](https://pubmed.ncbi.nlm.nih.gov/17189142/)
16. Coats DK, Paysse EA, Steinkuller PG (2000) Threshold retinopathy of prematurity in neonates less than 25 weeks' estimated gestational age. *J AAPOS* 4: 183–185. PMID: [10849397](https://pubmed.ncbi.nlm.nih.gov/10849397/)
17. Palmer EA, Hardy RJ, Dobson V, Phelps DL, Quinn GE, et al. (2005) 15-year outcomes following threshold retinopathy of prematurity: final results from the multicenter trial of cryotherapy for retinopathy of prematurity. *Arch Ophthalmol* 123: 311–318. PMID: [15767472](https://pubmed.ncbi.nlm.nih.gov/15767472/)
18. Hutchinson AK, Saunders RA, O'Neil JW, Lovering A, Wilson ME (1998) Timing of initial screening examinations for retinopathy of prematurity. *Arch Ophthalmol* 116: 608–612. PMID: [9596496](https://pubmed.ncbi.nlm.nih.gov/9596496/)
19. Cryotherapy for Retinopathy of Prematurity Cooperative Group (2002) Multicenter trial of cryotherapy for retinopathy of prematurity: natural history ROP: ocular outcome at 5(1/2) years in premature infants with birth weights less than 1251 g. *Arch Ophthalmol* 120: 595–599. PMID: [12003608](https://pubmed.ncbi.nlm.nih.gov/12003608/)
20. Carden SM, Luu LN, Nguyen TX, Huynh T, Good WV (2008) Retinopathy of prematurity: postmenstrual age at threshold in a transitional economy is similar to that in developed countries. *Clin Experiment Ophthalmol* 36: 159–161. doi: [10.1111/j.1442-9071.2008.01682.x](https://doi.org/10.1111/j.1442-9071.2008.01682.x) PMID: [18352873](https://pubmed.ncbi.nlm.nih.gov/18352873/)
21. Early Treatment for Retinopathy of Prematurity Cooperative Group, Good WV, Hardy RJ, Dobson V, Palmer EA, et al. (2010) Final visual acuity results in the early treatment for retinopathy of prematurity study. *Arch Ophthalmol* 128: 663–671. doi: [10.1001/archophthalmol.2010.72](https://doi.org/10.1001/archophthalmol.2010.72) PMID: [20385926](https://pubmed.ncbi.nlm.nih.gov/20385926/)
22. A Second International Committee for the Classification of Retinopathy of Prematurity (2005) The International Classification of Retinopathy of Prematurity—Revisited. *Arch Ophthalmol* 123: 991–999. PMID: [16009843](https://pubmed.ncbi.nlm.nih.gov/16009843/)
23. Coordination Group for the Survey of Present Status of Oxygen Use in Premature Infants in NICUs and Prevention and Treatment of ROP (2012) Present situation of oxygen therapy and retinopathy of prematurity management in premature infants in NICUs: a survey based on 16 tertiary class-one hospitals in the mainland of China. *Zhonghua Er Ke Za Zhi* 50: 167–171. PMID: [22801195](https://pubmed.ncbi.nlm.nih.gov/22801195/)
24. Chen Y, Li X (2006) Characteristics of severe retinopathy of prematurity patients in China: a repeat of the first epidemic? *Br J Ophthalmol* 90: 268–271. PMID: [16488941](https://pubmed.ncbi.nlm.nih.gov/16488941/)
25. Early Treatment for Retinopathy of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. *Arch Ophthalmol*: 1684–1696.
26. Good WV, Hardy RJ, Dobson V, Palmer EA, Phelps DL, et al. (2005) The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study. *Pediatrics* 116: 15–23. PMID: [15995025](https://pubmed.ncbi.nlm.nih.gov/15995025/)
27. Nguyen TH, Larson T, Engholm G, Moller H (2000) Increased adverse pregnancy outcomes with unreliable last menstruation. *Obstet Gynaecol* 95: 867–873. PMID: [10831983](https://pubmed.ncbi.nlm.nih.gov/10831983/)
28. Weller A, Weller L (1998) Assessment of menstrual regularity and irregularity using self-reports and objective criteria. *J Psychosom Obstet Gynaecol* 19: 111–116. PMID: [9638604](https://pubmed.ncbi.nlm.nih.gov/9638604/)
29. Hutchinson AK, Saunders RA, O'Neil JW, Lovering A, Wilson ME (1998) Timing of Initial Screening Examinations for Retinopathy of Prematurity. *Arch Ophthalmol* 116: 608–612. PMID: [9596496](https://pubmed.ncbi.nlm.nih.gov/9596496/)
30. Kelun Wei YY, Yujia Yao, Lizhang Du, Jiping Sun (2005) An initial epidemiologic investigation of preterm infants in cities of China. *Chinese Journal of Contemporary Pediatrics* 7: 25–28.